

SUPPLEMENTAL MATERIAL

Interpretation of incidental genetic findings localizing to genes associated with cardiac channelopathies and cardiomyopathies

Ezekian, JE, et al.

Supplemental Materials

Supplemental Table I:

Summary of ACMG-identified clinically actionable/reportable genes

Disease	Actionable/Reportable Genes*
Hypertrophic Cardiomyopathy	<i>ACTC1</i> [†] , <i>GLA</i> , <i>MYBPC3</i> [†] , <i>MYH7</i> [†] , <i>MYL2</i> , <i>MYL3</i> , <i>PRKAG2</i> , <i>TNNI3</i> [†] , <i>TNNT2</i> [†] , and <i>TPM1</i> [†]
Arrhythmogenic Right Ventricular Cardiomyopathy	<i>DSG2</i> , <i>DSP</i> , <i>DSC2</i> , <i>PKP2</i> , and <i>TMEM43</i>
Dilated Cardiomyopathy	<i>ACTC1</i> [†] , <i>LMNA</i> , <i>MYBPC3</i> [†] , <i>MYH7</i> [†] , <i>TNNI3</i> [†] , <i>TNNT2</i> [†] , and <i>TPM1</i> [†]
Catecholaminergic Polymorphic Ventricular Tachycardia	<i>RYR2</i>
Long QT Syndrome	<i>KCNQ1</i> , <i>KCNH2</i> , and <i>SCN5A</i> [‡]
Brugada Syndrome	<i>SCN5A</i> [‡]

*Based on 2013 ACMG guidelines on reporting of incidental findings in exome and genome sequencing⁶⁻⁸. [†]Genes overlap between HCM and DCM disease phenotypes. [‡] Gene overlap between LQTS and BrS disease phenotypes.

Supplemental Table II:

Prevalence, frequency, and signal-to-noise ratios of variants associated with inherited cardiac channelopathies and cardiomyopathies.

Disease	Disease Prevalence	Variant/Variant Frequency				Signal:Noise			Incidental Variant Prevalence vs Disease Prevalence*		Ref
		Pathogenic	Population	Incidental LP/P	Incidental VUS	Pathogenic: Population	Incidental LP/P: Population	Incidental VUS: Population	Incidental LP/P: Prevalence	Incidental VUS: Prevalence	
Hypertrophic cardiomyopathy	1 in 500	50%	5%	0.5%	6.8%	10:1	0.1:1	0.41:1	2.5-fold	34-fold	24-28
Arrhythmogenic right ventricular cardiomyopathy	1 in 5000	60%	16%	0.4%	14%	3.8:1	0.025:1	0.0875:1	20-fold	700-fold	29-30
Dilated cardiomyopathy	1 in 2500	30%	14%	N/A	N/A	2.14:1	N/A	N/A	N/A	N/A	31-35
Catecholaminergic polymorphic ventricular tachycardia	1 in 10,000	47%	6%	0.2%	9%	8.3:1	0.033:1	1.5:1	20-fold	900-fold	36-38
Long QT syndrome	1 in 2000	75%	10%	0.5%† 1.2%‡	11%† 37%‡	7.5:1	0.05:1† 0.12:1‡	1.1:1† 3.7:1‡	10-fold† 24-fold‡	220-fold 740-fold‡	39-41
Brugada syndrome	1 in 2,000	21%	5%	0.3%	6.3%	4.2:1	0.06:1	1.26:1	6-fold	126-fold	40,42

Variant frequency for each disease is based on variant classification. Pathogenic percentage denotes individuals positive for a pathogenic variant in one of the genes associated with disease. Population variants are rare variants found in a large population cohort. LP/P, incidentally identified likely pathogenic and/or pathogenic variants. N/A, not available or not identified. *Fold-difference between the prevalence of incidentally identified variants versus known disease prevalence in the community. Calculation based on presumption that all individuals with disease are genotype positive. †Only ACMG-designated actionable genes associated with LQTS (*KCNQ1*, *KCNH2*, and *SCN5A*), ‡All LQTS-associated genes

